Patients with newly-diagnosed glioblastoma (GBM), the most common and most malignant of all primary brain tumors, receive treatment with radiation and temozolomide in nearly all instances. The vast majority of such patients will have recurrent cancer within 2 years of completing treatment. Whereas much is known about the molecular characteristics of newly-diagnosed and untreated GBM, much less is known about recurrent and treated GBM, and there is a dearth of recurrent GBM models for testing therapies to treat recurrent tumor. This presentation will focus on my labs’ efforts in developing and characterizing patient-derived xenograft (PDX) models of recurrent and treated GBM, and will include discussion of potential uses for these models.
C. David James, Feinberg School of Medicine, Northwestern University
Host: Adilson Motter
Keywords: Physics, Astronomy, Complex Systems
Cristian Pennington
(847) 491-3645
Email